Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07043400 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase 3 study of Gastroesophageal Junction Adenocarcinoma and Metastatic Gastric Adenocarcinoma, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 351
- Enrollment target
- 20
- Study locations
NCT07043400 is a Phase 3 study of Gastroesophageal Junction Adenocarcinoma and Metastatic Gastric Adenocarcinoma that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 351 participants, below the 395-participant average among 40 other Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT07043400, a Phase 3 study of Gastroesophageal Junction Adenocarcinoma and Metastatic Gastric Adenocarcinoma, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 351 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Leucovorin
- DRUG Subcutaneous Tislelizumab
- DRUG Intravenous Tislelizumab
- DRUG 5-fluorouracil (5-FU)
Study Locations (20)
Other
- Krankenhaus Der Barmherzigen Schwestern Linz - Linz
- Hospital de Amor Barretos - Barretos
- CECAP - Blumenau
Florida
- Bioresearch Partners Holding Hialeah Hospital - Hialeah
- Orlando Health Ufhealth Cancer Center - Orlando
Illinois
- Northwestern University - Chicago
- Hope and Healing Cancer Services - Hinsdale
New Jersey
- Hunterdon Hematology Oncology - Flemington
- Summit Medical Group - Florham Park
Texas
- Md Anderson Cancer Center - Houston
- Scott and White Memorial Hospital - Temple
Arizona
- Ironwood Cancer and Research Centers - Chandler
California
- Cancer and Blood Specialty Clinic - Los Alamitos
Kansas
- University of Kansas Medical Center Research Institute - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2025-08-27 |
| Est. Completion | 2028-04-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07043400
The ClinicalTrials.gov registry entry for NCT07043400 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 395-participant average among 40 other Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (11% lower). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastroesophageal Junction Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT07043400 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT07043400 about?
NCT07043400 is a clinical study titled "A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma". This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot b...
What is the current status of trial NCT07043400?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 351 participants. The study started on 2025-08-27. Estimated completion is 2028-04-22.
What conditions does trial NCT07043400 study?
This clinical trial studies the following conditions: Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma.
What interventions are being tested in trial NCT07043400?
The interventions under investigation include: Cisplatin (DRUG), Leucovorin (DRUG), Subcutaneous Tislelizumab (DRUG), Intravenous Tislelizumab (DRUG), 5-fluorouracil (5-FU) (DRUG).
Who is sponsoring clinical trial NCT07043400?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07043400 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Junction Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
RECRUITING · Phase 3
-
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RECRUITING · Phase 3
-
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
ACTIVE NOT RECRUITING · Phase 3
-
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
RECRUITING · Phase 2
Explore more on PlainTrial
Gastroesophageal Junction Adenocarcinoma
All registered trials for this condition
Metastatic Gastric Adenocarcinoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.